Related Experiment Video
Updated: Jul 9, 2025
Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
Published on: August 19, 2020
Recurrence of Henoch Schoenlein Purpura Nephritis in Children: A Retrospective Study
Lydia Mukanhaire1,2,3, Xianguo Ren2, Guangling Liu3
1School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
Insights
Childhood Henoch-Schönlein Purpura (HSPN) relapse is predicted by disease severity, age (7-12 years), and treatment. Mycophenolate mofetil may reduce HSPN recurrence frequency.
Area of Science:
- Pediatric Nephrology
- Immunology
Background:
- Henoch-Schönlein Purpura (HSPN) is a common childhood vasculitis.
- Understanding predictors of HSPN relapse is crucial for management.
Purpose of the Study:
- To identify patient characteristics predicting relapse in childhood HSPN.
- To evaluate the impact of adjunctive therapies on HSPN recurrence.
Main Methods:
- Retrospective analysis of 135 Chinese children diagnosed with HSPN.
- Classification based on International Study of Kidney Disease in Children (ISKDC) criteria.
- Statistical correlation analysis of biopsy grade, gender, age, and treatment regimen with recurrence.
Main Results:
- HSPN recurrence observed in 66.3% of patients.
- Significant predictors for relapse included biopsy grade, male gender, age (7-12 years), and treatment regimen.
- Mycophenolate mofetil showed potential in reducing relapse frequency.
Conclusions:
- Disease severity, specific age groups, and treatment influence HSPN relapse.
- Mycophenolate mofetil may be a beneficial adjunctive therapy for reducing HSPN recurrence in children.
Abstract:
The aim of the study was to identify predictive patient characteristics for Henoch Schoenlein Purpura (HSPN) relapse in childhood HSPN. One hundred and thirty-five Chinese children with HSPN were enrolled in this study, mean age 10.25 ± 3.39 years. The pathology of HSPN was according to the International Study of Kidney Disease in Children criteria.(ISKDC); ISKDC II(mesangial proliferation (MP)) AND ISKDC III (MP with <50 % crescents).Recurrence of HSPN was observed in 66.3 % patients; male to female ratio (2:1)Statistically significant correlation existed between biopsy grade(p < 0.001), gender(p < 0.001),age ranges(p = 0.002) and treatment regimen (p < 0.001)in the frequency of recurrent HSPN episodes. We identified some significant predictors for HSPN relapse such as the severity of HSPN, adjunctive therapies administered to these patients,and close attention should be paid in patients between the ages 7 and 12 years old. In addition, the use of mycophenolate mofetil as an adjunctive therapy in the treatment of HSPN may reduce the frequency of HSPN relapse episodes in children.
